Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Osimertinib

4

I.av Transient pulmonary opacities/infiltrates (TAPO) (see also under IIj)

2
Last update : 30/12/2019
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist

Publications

Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting.
Chest 2022 Nov;162;1188-1198 2022 Nov
Welcome to the Real World: Understanding the Many Faces of Osimertinib-Related Pneumonitis.
Chest 2022 Nov;162;965-967 2022 Nov
Osimertinib in Pulmonary Manifestations: Two Case Reports and Review of the Literature.
In vivo (Athens, Greece) 2020;34;315-319 2020

Powered by

  • ^
  • Contact
  • Cookies
  • About